Related Experiment Video
Updated: Jul 15, 2026
Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
[From breast surgery to HER2 status: the role of the surgeon in molecular-targeted therapy]
1Szegedi Tudományegyetem, Szent-Györgyi Albert Orvos- és Gyógyszertudományi Centrum, Altalános Orvostudományi Kar, Onkoterápiás Klinika.
Abstract:
Clinical oncology has entered a new era these days: individualized molecular diagnostics and targeted therapy is becoming increasingly accepted. Implementation of these new possibilities has changed our view and the strategy of therapeutical decision-making. Transformed clinical praxis provides ever developing outcome. One of the best examples is trastuzumab, the first targeted therapy used for the treatment of HER2 positive tumors. Trastuzumab combined with the conventional therapies in the adjuvant setting dramatically improves the chance of cure. Surgeons have a dual role in the treatment of the patients: first, they remove the tumor which is the basis of curative treatment, and second, by providing tissue sample of appropriate quality for detailed pathological examinations, they promote correct and up-to-date oncological treatment. The contribution of surgeons is crucial for individualized postoperative therapy eventuating superior outcome.
Insights
Personalized medicine in oncology, including targeted therapies like trastuzumab for HER2-positive tumors, is improving patient outcomes. Surgeons play a vital role in providing high-quality tissue for diagnostics, enabling precise, individualized cancer treatment.
Area of Science:
- Oncology
- Molecular Diagnostics
- Targeted Therapy
Context:
- The field of clinical oncology is rapidly evolving with the integration of individualized molecular diagnostics and targeted therapies.
- This paradigm shift has significantly altered therapeutic decision-making strategies and improved patient outcomes.
- Trastuzumab, a targeted therapy for HER2-positive tumors, exemplifies the success of these advancements.
Purpose:
- To highlight the transformative impact of personalized medicine in oncology.
- To emphasize the critical role of surgeons in facilitating accurate molecular diagnostics and subsequent targeted treatments.
- To underscore how surgeon contributions enhance individualized postoperative therapy and patient outcomes.
Summary:
- Individualized molecular diagnostics and targeted therapies are revolutionizing cancer treatment.
- Trastuzumab demonstrates significant efficacy in HER2-positive tumors, particularly in the adjuvant setting when combined with conventional therapies.
- Surgeons are essential for tumor removal and providing quality tissue samples crucial for precise pathological examinations and tailored treatment plans.
Impact:
- Improved cure rates and superior outcomes for cancer patients through personalized treatment strategies.
- Enhanced collaboration between surgical and pathological departments for optimized oncological care.
- Advancement of precision medicine in clinical practice, leading to more effective and individualized cancer therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...